Comparison of suitable naïve versus pretreated DMO patients
Dr Javier Zarranz-Ventura discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.
Dr Javier Zarranz-Ventura, a vitreoretinal consultant at
Institut Clínic de Oftalmologia (ICOF), Hospital Clínic de Barcelona andInstitut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS), discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
